SFDA RWE Framework 2026: Digital PSP Data Collection in Saudi Arabia

The Saudi Food and Drug Authority published its Framework on the Use of Real-World Data and Real-World Evidence in April 2026, creating a formal regulatory pathway — and a formal compliance obligation — for pharmaceutical companies using patient support programs to generate real-world evidence in the Kingdom. For pharma companies running digital PSPs, the framework changes the data infrastructure requirements fundamentally: data quality standards, audit trails, and consent documentation that were previously governed by internal SOPs must now align with SFDA's published RWD/RWE criteria.

What the SFDA RWE Framework 2026 requires

The April 2026 framework draws on ICH E8(R1) and EMA's real-world evidence guidance while incorporating KSA-specific elements including PDPL compliance requirements and the role of NHIC data sources. Its core requirements affecting PSP digital infrastructure are:

Data quality and provenance standards

RWD used in regulatory submissions must meet SFDA's criteria: completeness, consistency, accuracy, and timeliness. For PSP-generated data — adherence records, adverse event reports, PROMs scores, nurse educator visit logs — the digital platform must maintain an immutable audit trail showing when each data point was recorded, by whom, and what system version was used. Retroactive data entry without logged justification will disqualify a dataset from RWE use.

Consent documentation requirements

Under PDPL and the new RWE framework, patient consent for PSP data to be used in regulatory evidence submissions must be specific — a general "data may be used for research" clause is insufficient. The consent form must name the purpose, the data elements to be shared, and the recipient. Digital PSP platforms must store a signed consent record linked to each patient identifier, with version control. [VERIFY WITH BRAND: consent versioning capabilities in CareSync PSP Connect]

Adverse event capture and pharmacovigilance alignment

The RWE framework explicitly states that AE data collected through PSPs qualifies as RWD for pharmacovigilance purposes if the platform meets minimum data standards. This elevates the importance of PSP platforms having medically reviewed AE intake forms, 15/7-day serious AE escalation workflows aligned with SFDA pharmacovigilance guidelines, and automatic triage logic. PSP platforms running manual AE logging via phone notes or paper cards are non-compliant.

Implications for pharma's digital PSP infrastructure

Most pharma companies running PSPs in KSA use one of three models: a proprietary platform, a regional white-label PSP platform, or a local CRO managing the program on paper/basic CRM. The SFDA RWE framework creates differentiated compliance risk:

Proprietary platforms — Likely have strong audit trails but may have been built before RWE requirements were formalised. A gap assessment is advisable.

White-label regional platforms — The SFDA framework requires the sponsor (not the platform vendor) to certify data quality. Pharma teams need to conduct vendor audits before the next regulatory submission cycle.

Paper/CRM-managed programs — These are incompatible with the RWE framework. Any pharma company planning to use PSP-generated data in a regulatory submission must migrate to a compliant digital platform. [VERIFY WITH BRAND: platform audit support for RWE readiness]

Five data infrastructure capabilities an SFDA-aligned PSP platform needs

1. Immutable audit log — Every data entry, edit, or deletion is logged with a timestamp, user ID, and reason for change.
2. Consent version control — Patient consent records link to a specific consent document version; new versions trigger re-consent workflows if the data use purpose changes.
3. Structured AE capture — AE intake uses a structured form aligned to E2B(R3) standards, with automatic 15/7-day serious AE escalation triggers.
4. PDPL-compliant data storage — Data must reside on Saudi servers; access logs must be exportable for SFDA inspections. [VERIFY WITH BRAND: server location and PDPL compliance certification]
5. Data export in regulatory-ready formats — The platform must export datasets compatible with SFDA's RWE submission package requirements.

CareSync PSP Connect is designed with regulatory-grade data architecture, including immutable audit logs, consent management with version control, and E2B(R3)-aligned AE intake forms. See the PSP platform overview for a detailed technical capability breakdown.

Connecting PSP RWE to label extensions and Phase IV submissions

The commercial value of an SFDA-compliant RWE dataset extends beyond pharmacovigilance. Pharma regulatory teams are using RWD/RWE from PSPs to support label extension applications, fulfil post-approval Phase IV commitments, and demonstrate real-world comparative effectiveness for payer negotiations with CCHI.

Key takeaways

• SFDA's April 2026 RWE Framework formalises data quality, consent, and AE documentation standards for PSP-generated real-world data.
• Paper-based and CRM-managed PSPs are incompatible with the framework's data quality criteria.
• Pharma sponsors — not platform vendors — are responsible for certifying RWD quality, making vendor audits a regulatory affairs priority.
• Five platform capabilities are non-negotiable: immutable audit logs, consent version control, structured E2B(R3) AE capture, PDPL-compliant storage, and regulatory-ready data export.
• Compliant PSP RWD unlocks label extensions, Phase IV fulfilment, and payer negotiations.

Frequently asked questions

When did the SFDA RWE Framework come into effect?

SFDA published the Framework on the Use of Real-World Data and Real-World Evidence in April 2026. It applies to regulatory submissions including RWD/RWE components from that date forward. [VERIFY WITH BRAND: framework effective date and transition provisions]

Does the SFDA RWE Framework apply to all PSPs, or only those generating data for regulatory submissions?

The framework applies specifically to RWD/RWE intended for regulatory use. However, SFDA's pharmacovigilance guidelines — requiring structured AE capture and 15/7-day escalation — apply to all PSPs as a baseline.

What is the difference between RWD and RWE under the SFDA framework?

Real-world data (RWD) is the raw data collected from PSPs, EHRs, and claims databases. Real-world evidence (RWE) is the clinical evidence derived from RWD through analysis. The framework applies quality criteria to RWD and analytical rigor standards to RWE.

Can a PSP platform pass the SFDA RWE data quality audit without a formal GxP validation?

The framework does not mandate GxP computer system validation for PSP platforms, but it requires the sponsor to demonstrate data integrity, audit trail completeness, and consent documentation accuracy.

How does CareSync PSP Connect support SFDA RWE framework compliance?

CareSync PSP Connect provides immutable audit logs, consent management with version control, E2B(R3)-structured AE intake, PDPL-compliant Saudi-hosted data storage, and CSV/structured data exports for regulatory submissions. [VERIFY WITH BRAND: regulatory compliance certification status]

References

1. SFDA. Framework on the Use of Real-World Data and Real-World Evidence. April 2026. sfda.gov.sa
2. ICH E8(R1). General Considerations for Clinical Studies, 2021.
3. EMA. Guidance on Use of Real-World Data in Regulatory Submissions, 2022.
4. SFDA Pharmacovigilance Guidelines for MAHs, 2023. sfda.gov.sa
5. PDPL, Saudi Arabia. Personal Data Protection Law, Royal Decree M/19, 2021.

Editorial framework by CareSync Medical Team. This operational planning article does not establish regulatory approval, certification or clinical effectiveness.